Switching PAH medicines: does it change your risk?
Part of Lungs & breathing clinical trials.
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a firm diagnosis of pulmonary arterial hypertension (PAH), confirmed by a special heart test called right heart catheterization.
- You should have either switched from ambrisentan to bosentan within the last 6 months, or been on ambrisentan for at least 6 months without switching.
- You must not have severe liver problems.
- You must have complete medical records and be able to attend a follow-up visit 3 to 6 months after the switch.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This study tests whether regular remote check-ins and guidance can help people with pulmonary arterial hypertension stick to their treatment plan. You would be followed by phone or video from University of Sao Paulo.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.